Research.Patient.info
Ovarian Cancer Recurrent research hub
2 indexed studies · 2 currently recruiting
- recruitingPHASE1, PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
This study looks at new ways to treat ovarian cancer that has come back after earlier treatments. It tests a new drug called Raludotatug deruxtecan (R-DXd) by itself or with other standard treatments, to see if it's safe and helps shrink the cancer.
United States · Israel · Spain - recruitingPHASE2
SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
This study looks at combining targeted radiotherapy (SBRT) with an ovarian cancer drug (niraparib) for women whose cancer has shown small areas of growth or comeback after previous treatment with a PARP inhibitor. It aims to see if this combination helps manage the cancer.
United Kingdom